Group 1 - LifeStance Health Group (LFST) closed at $5.95, with an 8% gain over the past four weeks, and a mean price target of $8.63 indicates a 45% upside potential [1] - The average price targets from analysts range from $7 to $10, with a standard deviation of $1.03, suggesting a variability in estimates; the lowest estimate indicates a 17.7% increase, while the highest points to a 68.1% upside [2] - Analysts show strong agreement on LFST's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for LFST has increased by 43.6% due to four upward revisions in earnings estimates over the last 30 days, with no negative revisions [12] - LFST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While price targets may not be reliable indicators of the extent of gains, they can provide a directional guide for price movement [10][13]

Core Viewpoint - Synaptics (SYNA) shares have increased by 7.3% recently, closing at $62.48, with a potential upside of 40.6% based on Wall Street analysts' mean price target of $87.86 [1] Group 1: Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $11.85, indicating variability among analysts [2] - The lowest price target of $80 suggests a 28% increase, while the highest target of $105 indicates a potential surge of 68.1% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Group 2: Earnings Estimates and Analyst Agreement - Strong agreement among analysts regarding SYNA's earnings prospects supports the expectation of an upside, as indicated by positive revisions in EPS estimates [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 62.3%, with three estimates moving higher and no negative revisions [12] - SYNA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - Immunocore Holdings PLC (IMCR) shares have increased by 20.2% over the past four weeks, closing at $36.60, with a mean price target of $60.47 indicating a potential upside of 65.2% [1] - The average of 15 short-term price targets ranges from a low of $24 to a high of $100, with a standard deviation of $21.18, suggesting variability in analyst estimates [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the expectation of an upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 42.9% over the past month, with seven estimates revised higher and no negative revisions [12] - IMCR holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can indicate the direction of price movement, which appears to be a good guide [13]

Core Viewpoint - Nexxen International Ltd. (NEXN) has seen a 16.4% increase in share price over the past four weeks, closing at $11.72, with a potential upside of 25.2% based on Wall Street analysts' mean price target of $14.67 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $2.55, indicating variability among analysts; the lowest estimate is $9 (23.2% decline), while the highest is $18 (53.6% increase) [2][9]. - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about NEXN's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11][12]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 10.8%, with one estimate moving higher and no negative revisions [12]. Zacks Rank and Investment Potential - NEXN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13].

Group 1 - Instil Bio, Inc. (TIL) has seen a significant stock price increase of 108.2% over the past four weeks, closing at $26.75, with a mean price target of $118.67 indicating a potential upside of 343.6% [1] - The mean estimate includes three short-term price targets with a standard deviation of $64.73, where the lowest estimate of $51 suggests a 90.7% increase, and the most optimistic target is $180, indicating a potential surge of 572.9% [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as the Zacks Consensus Estimate for the current year has increased by 7.2% over the last 30 days [11][12] Group 2 - TIL holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] - While price targets are often viewed skeptically due to their historical inaccuracy, a tight clustering of targets with low standard deviation indicates a high degree of agreement among analysts regarding the stock's price direction [9][10] - The positive trend in earnings estimate revisions is a more reliable indicator of potential stock performance than price targets alone, as empirical research supports this correlation [11]

Shares of Encore Capital Group (ECPG) have gained 11.1% over the past four weeks to close the last trading session at $39.04, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $57.25 indicates a potential upside of 46.6%.The average comprises four short-term price targets ranging from a low of $55 to a high of $61, with a standard deviation of $2.63. While the lowest estimate indi ...

Group 1 - BioCryst Pharmaceuticals (BCRX) closed at $10.59, with a 26.2% gain over the past four weeks, and a mean price target of $16.50 indicating a 55.8% upside potential [1] - The average of 12 short-term price targets ranges from a low of $11 to a high of $30, with a standard deviation of $5.32, suggesting variability in analyst estimates [2] - Analysts show strong agreement on BCRX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 366.9% over the past month, with six estimates revised higher and no negative revisions [12] - BCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate potential price movement direction [13]

Group 1 - The stock of Pediatrix Medical Group (MD) closed at $13.56, reflecting a 10.7% gain over the past four weeks, with a mean price target of $17.14 indicating a potential upside of 26.4% [1] - The mean estimate consists of seven short-term price targets with a standard deviation of $2.61, where the lowest estimate is $14 (3.2% increase) and the highest is $21 (54.9% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings than previously predicted, which supports the view of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.1% over the past month, with two estimates revised higher and no negative revisions [12] - MD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While the consensus price target may not be entirely reliable, the direction it implies appears to be a good guide for potential price movement [13]

Group 1 - Shift4 Payments (FOUR) shares have increased by 17.2% over the past four weeks, closing at $90.26, with a mean price target of $114.83 indicating a potential upside of 27.2% [1] - The average of 23 short-term price targets ranges from a low of $80 to a high of $150, with a standard deviation of $15.53, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 20.2% over the past month [11][12] Group 2 - FOUR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The correlation between earnings estimate revisions and near-term stock price movements supports the expectation of an upside in FOUR [11] - While price targets are often viewed skeptically, the direction implied by the consensus price target may serve as a useful guide for potential price movement [10][13]

Core Viewpoint - Karyopharm Therapeutics (KPTI) shows significant upside potential with a mean price target of $33.07, indicating a 521.6% increase from its current price of $5.32 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from $8 to $67.47, with a standard deviation of $23.37, suggesting a high variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 50.4%, while the highest suggests an upside of 1168.2% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts exhibit strong agreement in revising KPTI's earnings estimates higher, which correlates with potential stock price increases [4][11] - Over the past 30 days, one estimate has increased, leading to a 4.9% rise in the Zacks Consensus Estimate for the current year [12] - KPTI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]